RVMD News and Press, Revolution Medicines Inc. From 10/04/23

Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE ...

2023-09-28 16:18:43 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript Mira...

2023-09-25 15:24:12 ET Summary Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The company is focusing on developing RAS(ON) inhibitors, which target the active form of KRAS, with sev...

2023-09-25 09:00:00 ET Summary Revolution Medicines boasts a strong cash position of $909.5M and a focus on RAS-targeted oncology but faces increased expenses and high clinical expectations. Upcoming clinical data for RMC-6236 and the EQRx acquisition are key catalysts that could ...

KRAS G12D (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRAS G12D mutation, the most common driver of RAS-addicted human cancers REDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc....

Science Report on KRAS G12C (ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology c...

2023-08-08 23:05:08 ET Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Conference Call August 08, 2023 4:30 PM ET Company Participants Erin Graves – Senior Director of Corporate Communications and Investor Relations Mark Goldsmith – Chairman and Chie...

2023-08-08 16:34:19 ET Revolution Medicines press release ( NASDAQ: RVMD ): Q2 GAAP EPS of -$0.92 misses by $0.09 . Revenue of $3.82M (-58.1% Y/Y) beats by $2.26M . For further details see: Revolution Medicines GAAP EPS of -$0.92 misses by $0.09, revenue ...

Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and...

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8...